Evaluation of nootropic and neuroprotective effects of low dose aspirin in rats
- PMID: 21701638
- PMCID: PMC3117566
- DOI: 10.4103/0976-500X.77079
Evaluation of nootropic and neuroprotective effects of low dose aspirin in rats
Abstract
Objective: To evaluate the nootropic and neuroprotective effects of aspirin in Sprague Dawley rats.
Materials and methods: Retention of conditioned avoidance response (CAR) and central 5-HT-mediated behavior (lithium-induced head twitches) were assessed using repeated electroconvulsive shock (ECS) in rats. Rats were divided into eight groups: control (pretreated with distilled water), scopolamine (0.5 mg/kg i.p.), ECS (150 V, 50 Hz sinusoidal with intensity of 210 mA for 0.5 s) pretreated, aspirin (6.75 mg/kg orally) pretreated, combined scopolamine and aspirin pretreated, ondansetron (0.36 mg/kg orally) pretreated, combined ECS and ondansetron pretreated and combined ECS and aspirin pretreated groups. Data was analyzed by the chi-square test and ANOVA.
Results: Findings show that administration of single ECS daily for consecutive 8 days results in enhancement of 5-HT-mediated behavior (lithium-induced head twitches) and in disruption of the retention of CAR. Aspirin and ondansetron administration significantly increased the retention of conditioned avoidance response compared to control. Ondansetron and aspirin significantly prevented ECS-induced attenuation of the retention of conditioned avoidance response also. On the other hand, ondansetron and aspirin significantly retarded the ECS-induced enhancement of 5-HT-mediated behavior.
Conclusion: Inhibition of the serotonergic transmission by aspirin is responsible for its nootropic and neuroprotective actions.
Keywords: Aspirin; conditioned avoidance response; lithium induced head twitches; serotonergic transmission.
Conflict of interest statement
Figures
References
-
- Rang HP, Dale MM, Ritter JM, Flower RJ, editors. Rang and Dale’s Pharmacology. China: Elsevier; 2007. Anti-inflammatory and immunosuppressant drugs; pp. 234–5.
-
- Melander A, McClearn G, Johansson B, Nilsson SE, Takkinen S, Berg S, et al. Does aspirin protest against Alzheimer’s dementia? A study in a Swedish population-based sample aged ≥ 80 years. Eur J Clin Pharmacol. 2003;59:313–9. - PubMed
-
- Geerts H, Grossberg GT. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in treatment of Alzheimer’s disease. J Clin Pharmacol. 2006;46:8S–16S. - PubMed
-
- Giacobini E. Cholinergic function and Alzheimer’s disease. Int J Geriatr Psychiatry. 2003;18:S1–5. - PubMed
-
- Mesulam M. The cholinergic lesion of Alzheimer’s disease: Pivotal factor or side show? Learn Mem. 2004;11:43–9. - PubMed
LinkOut - more resources
Full Text Sources